Issues involving rare disease therapies.
2026 · 3rd Quarter (July 1 - Sep 30)
OMEROS CORPORATION
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- OMEROS CORPORATION
- Filing UUID
- b5728520-391e-471c-8a9b-7cfc5a53ef4b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to rare pediatric disease and Priority Review Vouchers (PRVs). H.R. 10359, Priority for Pediatric Cures Act.
Literal federal measure citations: H.R. 10359
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.